http://purl.org/np/RAjzABm884LI7bMA2Jm7e1Z0IaCYid-SYhzp1nfe4TVNY#Head
http://purl.org/np/RAjzABm884LI7bMA2Jm7e1Z0IaCYid-SYhzp1nfe4TVNY
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RAjzABm884LI7bMA2Jm7e1Z0IaCYid-SYhzp1nfe4TVNY#assertion
http://purl.org/np/RAjzABm884LI7bMA2Jm7e1Z0IaCYid-SYhzp1nfe4TVNY
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RAjzABm884LI7bMA2Jm7e1Z0IaCYid-SYhzp1nfe4TVNY#provenance
http://purl.org/np/RAjzABm884LI7bMA2Jm7e1Z0IaCYid-SYhzp1nfe4TVNY
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RAjzABm884LI7bMA2Jm7e1Z0IaCYid-SYhzp1nfe4TVNY#pubinfo
http://purl.org/np/RAjzABm884LI7bMA2Jm7e1Z0IaCYid-SYhzp1nfe4TVNY
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RAjzABm884LI7bMA2Jm7e1Z0IaCYid-SYhzp1nfe4TVNY#assertion
http://purl.obolibrary.org/obo/DOID_14330
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RAjzABm884LI7bMA2Jm7e1Z0IaCYid-SYhzp1nfe4TVNY#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_14330
http://purl.org/np/RAjzABm884LI7bMA2Jm7e1Z0IaCYid-SYhzp1nfe4TVNY#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RAjzABm884LI7bMA2Jm7e1Z0IaCYid-SYhzp1nfe4TVNY#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB00190
http://purl.org/np/RAjzABm884LI7bMA2Jm7e1Z0IaCYid-SYhzp1nfe4TVNY#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RAjzABm884LI7bMA2Jm7e1Z0IaCYid-SYhzp1nfe4TVNY#association
http://www.w3.org/2000/01/rdf-schema#label
carbidopa tablets are indicated for use with carbidopa levodopa or with levodopa in the treatment of the symptoms of idiopathic parkinson s disease paralysis agitans postencephalitic parkinsonism and symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication and or manganese intoxication carbidopa tablets are for use with carbidopa levodopa in patients for whom the dosage of carbidopa levodopa provides less than adequate daily dosage usually 7 mg daily of carbidopa carbidopa tablets are for use with levodopa in the occasional patient whose dosage requirement of carbidopa and levodopa necessitates separate titration of each medication carbidopa tablets are used with carbidopa levodopa or with levodopa to permit the administration of lower doses of levodopa with reduced nausea and vomiting more rapid dosage titration and with a somewhat smoother response however patients with markedly irregular on off responses to levodopa have not been shown to benefit from the addition of carbidopa since carbidopa prevents the reversal of levodopa effects caused by pyridoxine supplemental pyridoxine vitamin b6 can be given to patients when they are receiving carbidopa and levodopa concomitantly or as carbidopa levodopa although the administration of carbidopa tablets permits control of parkinsonism and parkinson s disease with much lower doses of levodopa there is no conclusive evidence at present that this is beneficial other than in reducing nausea and vomiting permitting more rapid titration and providing a somewhat smoother response to levodopa certain patients who responded poorly to levodopa alone have improved when carbidopa and levodopa were given concurrently this was most likely due to decreased peripheral decarboxylation of levodopa rather than to a primary effect of carbidopa on the peripheral nervous system carbidopa has not been shown to enhance the intrinsic efficacy of levodopa in deciding whether to give carbidopa tablets with carbidopa levodopa or with levodopa to patients who have nausea and or vomiting the physician should be aware that while many patients may be expected to improve some may not since one cannot predict which patients are likely to improve this can only be determined by a trial of therapy it should be further noted that in controlled trials comparing carbidopa and levodopa with levodopa alone about half the patients with nausea and or vomiting on levodopa alone improved spontaneously despite being retained on the same dose of levodopa during the controlled portion of the trial
http://purl.org/np/RAjzABm884LI7bMA2Jm7e1Z0IaCYid-SYhzp1nfe4TVNY#association
https://w3id.org/biolink/vocab/association_type
https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation
http://purl.org/np/RAjzABm884LI7bMA2Jm7e1Z0IaCYid-SYhzp1nfe4TVNY#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RAjzABm884LI7bMA2Jm7e1Z0IaCYid-SYhzp1nfe4TVNY#association
https://w3id.org/biolink/vocab/relation
https://w3id.org/um/neurodkg/SymptomaticReliefIndication
https://identifiers.org/drugbank:DB00190
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RAjzABm884LI7bMA2Jm7e1Z0IaCYid-SYhzp1nfe4TVNY#provenance
http://purl.org/np/RAjzABm884LI7bMA2Jm7e1Z0IaCYid-SYhzp1nfe4TVNY#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAjzABm884LI7bMA2Jm7e1Z0IaCYid-SYhzp1nfe4TVNY#pubinfo
http://purl.org/np/RAjzABm884LI7bMA2Jm7e1Z0IaCYid-SYhzp1nfe4TVNY#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RAjzABm884LI7bMA2Jm7e1Z0IaCYid-SYhzp1nfe4TVNY#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RAjzABm884LI7bMA2Jm7e1Z0IaCYid-SYhzp1nfe4TVNY#sig
http://purl.org/nanopub/x/hasSignature
da7oQRjxLEvtjr901s4hRZWUyB+4F0v6ZkgHobQFaXztoRcCIh5RNoiBoujY5Kw9FVL8oLJBvlc7FpNhTA67WOun75ttKqe3WWd4Syq8nDEUOaqHCq26gjR07d6YKDdjyE3E1AxbGRop6jE8f2fYLdiA+LP/nso5tqnA/OJIg80=
http://purl.org/np/RAjzABm884LI7bMA2Jm7e1Z0IaCYid-SYhzp1nfe4TVNY#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RAjzABm884LI7bMA2Jm7e1Z0IaCYid-SYhzp1nfe4TVNY
http://purl.org/np/RAjzABm884LI7bMA2Jm7e1Z0IaCYid-SYhzp1nfe4TVNY
http://purl.org/dc/terms/created
2021-06-13T15:08:22.347+02:00
http://purl.org/np/RAjzABm884LI7bMA2Jm7e1Z0IaCYid-SYhzp1nfe4TVNY
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAjzABm884LI7bMA2Jm7e1Z0IaCYid-SYhzp1nfe4TVNY
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RAjzABm884LI7bMA2Jm7e1Z0IaCYid-SYhzp1nfe4TVNY
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RAjzABm884LI7bMA2Jm7e1Z0IaCYid-SYhzp1nfe4TVNY
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs